Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
Expands Wellness Platform with Targeted GLP-1 Support Products Focused on Fiber, Vitality, and Protein Kick. Sports Nutrition® Expands with New Flavor Innovations Across Protein and Pre- and Post-Wor
Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore
01:15am, Wednesday, 11'th Feb 2026
Viking Therapeutics is advancing weight loss candidates through phase 2 and phase 3 trials. Results so far have been very promising.
Why Cheaper GLP-1 Drugs Are Facing Legal Battles
01:01pm, Tuesday, 10'th Feb 2026
The push to make weight loss drugs more affordable is running into legal limits. Telehealth company Hims & Hers pulled a less expensive oral version of Wegovy after lawsuits from Novo Nordisk and risi
Thinking About Investing in GLP-1 Stocks? Here Are 3 Things You Need to Know
01:00pm, Tuesday, 10'th Feb 2026
The growth potential in the GLP-1 market could help healthcare stocks soar in value. Competition, however, is likely to be fierce.
Hims & Hers Health: The GLP-1 Trade Just Got Real (Rating Downgrade)
09:53am, Tuesday, 10'th Feb 2026
Downgrading Hims & Hers Health, Inc. to Hold as the GLP-1 downside catalysts feel very real now. The FDA signaled new limits on non-approved compounded GLP-1 APIs being mass-marketed, and it explicitl
Eli Lilly Is Partnering with Gene-Editing Start-up Seamless Therapeutics. Here's What Investors Need to Know.
09:15am, Tuesday, 10'th Feb 2026
Eli Lilly's GLP-1 drugs have seen strong demand, which has investors excited about the future. The company knows that its GLP-1 success won't last forever and is exploring additional paths.
Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains?
03:50am, Tuesday, 10'th Feb 2026
Demand for weight loss drugs is high, and analysts predict the market may reach nearly $100 billion in a few years. Eli Lilly dominates the GLP-1 market in the U.S. We're bullish on these 10 stocks �
Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast?
04:07pm, Monday, 09'th Feb 2026
On Friday, the U.S. Food and Drug Administration said it would take "decisive steps" to restrict GLP-1 ingredients in compounded drugs not approved by the agency. Last week, Hims & Hers announced plan
Chipotle Is Now Targeting the GLP-1 Market. Can This Move Turn Things Around for the Struggling Restaurant Chain?
12:29pm, Monday, 09'th Feb 2026
Chipotle recently launched new menu items that appear to be targeted at more diet-conscious consumers and those now using GLP-1 drugs. GLP-1 drugs suppress one's appetite.
Over 60% of Eli Lilly's Revenue Comes From Its GLP-1 Drugs. Should Investors Be Worried?
11:30am, Monday, 09'th Feb 2026
Eli Lilly's fourth-quarter revenue rose by 43%, largely a result of its impressive GLP-1 products. Sales from its GLP-1 drugs doubled, and they are key components of the company's business.
Novo Nordisk Stock Whipsawed by GLP-1 Pill Fears: Relief Ahead?
10:56am, Monday, 09'th Feb 2026
NVO shares swing sharply after fears over cheap compounded GLP-1 pills, before FDA action and a Hims retreat spark a sharp rebound.
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
09:30pm, Saturday, 07'th Feb 2026
Eli Lilly's stock price rose sharply as demand for its GLP-1 drugs increased. Novo Nordisk is the second fiddle in GLP-1 drugs, but its GLP-1 pill is seeing strong demand.
FDA Targets Hims & Hers, Other Marketers of Unapproved GLP-1 Weight-Loss Drugs
06:23pm, Friday, 06'th Feb 2026
The FDA said “decisive steps” will be taken to restrict drugs using GLP-1 active pharmaceutical ingredients in non-approved drugs.
San Francisco, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice.
New York, NY, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice.
